Matthias Müller

Präexpositionsprophylaxe für Frauen: Eine neue Ära der HIV-Prävention Eine vielversprechende Option zur Verhinderung von HIV-Neuinfektionen könnte der Kapsidinhibitor Lenacapavir sein. Aufgrund seiner Depotwirkung muss er nur zweimal im Jahr injiziert werden, was die Prävention erheblich vereinfachen könnte.

Gerade erschienen! HIV PrEP mit langwirksamer Lenacapavir-Injektion. Darum läutet sie gerade für Frauen in Afrika eine neue Ära ein:

Präexpositionsprophylaxe für Frauen: Eine neue Ära der HIV-Prävention Eine vielversprechende Option zur Verhinderung von HIV-Neuinfektionen könnte der Kapsidinhibitor Lenacapavir sein. Aufgrund seiner Depotwirkung muss er nur zweimal im Jahr injiziert werden, was die Prävention erheblich vereinfachen könnte.

Gerade erschienen! HIV PrEP mit langwirksamer Lenacapavir-Injektion. Darum läutet sie gerade für Frauen in Afrika eine neue Ära ein:

Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections | NEJM Bloodstream infections are associated with substantial morbidity and mortality. Early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain. In a multicenter, non...

Now it’s official: 7 days of antibiotics are enough for most uncomplicated bloodstream infections – only S. aureus still needs special attention www.nejm.org/doi/full/10....

Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections | NEJM Bloodstream infections are associated with substantial morbidity and mortality. Early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain. In a multicenter, non...

Now it’s official: 7 days of antibiotics are enough for most uncomplicated bloodstream infections – only S. aureus still needs special attention www.nejm.org/doi/full/10....

Watching list
#HIVsky #IDsky

Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/​FTC in MSM in Thailand and France. (SimpPrEP)

TAF/FTC 1:1
TDF/FTC 2:1:1

clinicaltrials.gov/study/NCT058...

‘HIV-ending’ drug could be made for just $25 per patient a year, say researchers As regulator prepares to approve Lenacapavir in the US, campaigners are urging the manufacturer, Gilead, to make it ‘available and affordable for all who need it’

www.theguardian.com/society/2025...

Will long-lasting HIV preventive be a game changer—or a missed opportunity? FDA’s approval of lenacapavir comes at a time when global health cuts could stall its rollout

www.science.org/content/arti...

Will long-lasting HIV preventive be a game changer—or a missed opportunity? FDA’s approval of lenacapavir comes at a time when global health cuts could stall its rollout

www.science.org/content/arti...

‘HIV-ending’ drug could be made for just $25 per patient a year, say researchers As regulator prepares to approve Lenacapavir in the US, campaigners are urging the manufacturer, Gilead, to make it ‘available and affordable for all who need it’

www.theguardian.com/society/2025...

Will long-lasting HIV preventive be a game changer—or a missed opportunity? FDA’s approval of lenacapavir comes at a time when global health cuts could stall its rollout

The goal has to be reaching people who have never used PrEP before, Beatriz Grinsztejn says. “The fear I have is that this becomes mostly available for those who are already doing well on oral PrEP,” she says
🧪 #IDsky

FDA Approves Gilead’s Twice-Yearly Injectable Lenacapavir for HIV Prevention Gilead’s long-acting HIV capsid inhibitor shows 96–100% efficacy in phase 3 trials and aims to expand access worldwide through regulatory filings and support programs.

❗BREAKING: FDA approved Gilead Sciences Yeztugo (lenacapavir) for HIV-1 PrEP, the first twice-yearly injectable option. The approval is based on the PURPOSE trials showing ≥99.9% prevention efficacy. #IDsky #MEDsky #HIVsky

Our interview with Dr. Jared Baeten: www.contagionlive.com/view/fda-app...

Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort Time-updated analyses of the REPRIEVE cohort suggest that antiretroviral therapies featuring abacavir backbones increase hazard of major adverse cardiovasc

Risk for major adverse cardiovascular events (MACE) among individuals with HIV infection higher in those receiving abacavir- vs tenofovir-based antiretroviral therapy (ART). (Study) #IDSky #HIV

academic.oup.com/ofid/article...

🫁 Join the European Advanced Course in Clinical Tuberculosis 2025!
🗓️ June 25–27 | 📍 Borstel, Germany
💡 Cutting-edge TB science, clinical updates & networking with global experts.
🔗 Register by June 8! www.dzif.de/en/event/eur...
#TB2025 #ClinicalTB #InfectiousDiseases #EACCTB

😞

Klimapolitik: Michael Kretschmer will deutsche Klimaziele auf 2050 verschieben 2045 will Deutschland klimaneutral sein – Sachsens Ministerpräsident Michael Kretschmer fordert, das Ziel zu verschieben. Auch das Tempo beim Windkraftausbau sei falsch.

Kretschmer will das #Klimaziel auf 2050 verschieben.
Heißt übersetzt: Deutschland soll sich fünf Jahre mehr Zeit lassen, um noch mehr Zeit zu verlieren.

Das ist nicht konservativ – das ist kapitulierend‼️

www.zeit.de/politik/deut...

😨 3 Fälle mit XDR Gonokokken in Deutschland. An Therapiekontrolle denken! 3 cases of XDR gonorrhea reported in Germany. Remember to follow up with therapy control!
content://media/external_primary/downloads/1000018858

😨 3 Fälle mit XDR Gonokokken in Deutschland. An Therapiekontrolle denken! 3 cases of XDR gonorrhea reported in Germany. Remember to follow up with therapy control!
content://media/external_primary/downloads/1000018858

See you #EACS2025, @eacsociety.bsky.social, @aides-paris.bsky.social,

I am confused: only RCT "Doxyvac" shows no efficacy of the 4CmenB vaccine for gonorrhoea. So, what's the rationale of NHS? @rki.de, @paulsax, @fabian-juzek.bsky.social #InfectiousDiseases

@aides-paris.bsky.social. Dear aides-paris team, Would it be possible to get one of your wonderful posters for my HIV practice? (www.zweigpraxis-clotten.de)

I am confused: only RCT "Doxyvac" shows no efficacy of the 4CmenB vaccine for gonorrhoea. So, what's the rationale of NHS? @rki.de, @paulsax, @fabian-juzek.bsky.social #InfectiousDiseases

Discovered today in Paris:"We didn't live through the fall of the Berlin Wall, but we will witness the end of AIDS"

See you #EACS2025, @eacsociety.bsky.social

See you #EACS2025, @eacsociety.bsky.social, @aides-paris.bsky.social,

See you #EACS2025, @eacsociety.bsky.social

Discovered today in Paris:"We didn't live through the fall of the Berlin Wall, but we will witness the end of AIDS"

Breakfast in bed, in front of a train window with sunrise outside.

Nighttrain journey to Vienna for #ESCMIDGlobal. Looking forward to five days of discussing all things infectiousdiseases & clinical microbiology!🦠 #IDSky @escmid.bsky.social @taescmid.bsky.social @esgap.bsky.social

#IDSky #MedSky #GynSky
Adding treatment of the male partner (Metronidazole 400 mg po BID + topical 2% clinda to penile skin BID x 7 days) of females with bacterial vaginosis (BV) decreases recurrent BV within 12 weeks by 63% compared with treating females alone.

www.nejm.org/doi/full/10....

Trump: 'Thank you for partnering with USAID and God bless America.' - Bhekisisa In today’s newsletter, Mia Malan explains how US President Donald Trump ordered USAID-funded HIV organisations in SA to shut down. Sign up for our newsletter today. THIS IS A BREAKING, DEVELOPING STOR...

“Saving dollars and spending lives — no words!"